kynurenic acid has been researched along with Inflammation in 58 studies
Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.
kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether functional vitamin B-6 insufficiency occurs in OC users and is attributable to OCs, we investigated the associations of PLP with metabolites of one-carbon metabolism, tryptophan catabolism, and inflammation in OC users, and evaluated the effects of OCs on these metabolites." | 9.20 | Metabolite profile analysis reveals association of vitamin B-6 with metabolites related to one-carbon metabolism and tryptophan catabolism but not with biomarkers of inflammation in oral contraceptive users and reveals the effects of oral contraceptives o ( Chi, YY; Coats, B; Gregory, JF; Midttun, Ø; Rios-Avila, L; Stacpoole, PW; Ueland, PM, 2015) |
| "Tryptophan catabolites (TRYCATs) are implicated in the pathophysiology of mood disorders by mediating immune-inflammation and neurodegenerative processes." | 9.12 | Tryptophan Catabolites in Bipolar Disorder: A Meta-Analysis. ( Coppens, V; De Picker, L; Giltay, EJ; Hebbrecht, K; Morrens, M; Skorobogatov, K, 2021) |
| "Our results suggest that periodontal inflammation plays a role in local and systemic tryptophan-kynurenine metabolism." | 8.12 | Influence of periodontal inflammation on tryptophan-kynurenine metabolism: a cross-sectional study. ( Akdoğan, N; Altıngöz, SM; Balcı, N; Günhan, M; Kurgan, Ş; Önder, C; Serdar, MA, 2022) |
| "046), and neopterin was associated with the combined endpoint (recurrent ischemic stroke or death) (HR 1." | 8.02 | Neopterin and kynurenic acid as predictors of stroke recurrence and mortality: a multicentre prospective cohort study on biomarkers of inflammation measured three months after ischemic stroke. ( Alme, KN; Askim, T; Assmus, J; Knapskog, AB; Mollnes, TE; Naik, M; Næss, H; Saltvedt, I; Ueland, PM; Ulvik, A, 2021) |
| "Tryptophan catabolites ("TRYCATs") produced by the kynurenine pathway (KP) may play a role in depression pathophysiology." | 8.02 | The association between plasma tryptophan catabolites and depression: The role of symptom profiles and inflammation. ( Allers, KA; Beekman, ATF; Giltay, EJ; Keller, S; Milaneschi, Y; Niessen, HG; Penninx, BWJH; Schoevers, RA; Süssmuth, SD, 2021) |
| "While both adipose tissue accumulation and tryptophan metabolism alterations are features of human immunodeficiency virus (HIV) infection, their interplay is unclear." | 7.96 | Abdominal Adipose Tissue Is Associated With Alterations in Tryptophan-Kynurenine Metabolism and Markers of Systemic Inflammation in People With Human Immunodeficiency Virus. ( Gelpi, M; Lebech, AM; Lundgren, J; Midttun, Ø; Mocroft, A; Nielsen, SD; Trøseid, M; Ueland, PM; Ullum, H, 2020) |
| "Kynurenine pathway (KP) metabolites are believed to be a link between inflammation and depression through effects on brain glutamate receptors." | 7.96 | Associations among peripheral and central kynurenine pathway metabolites and inflammation in depression. ( Baer, W; Felger, JC; Goldsmith, DR; Haroon, E; Miller, AH; Patel, T; Welle, JR; Woolwine, BJ, 2020) |
| "Kynurenic acid (KA), an endogenous product of L-tryptophan metabolism in the kynurenine pathway, regulates adipose tissue energy homeostasis and inflammation." | 7.96 | Administration of kynurenic acid reduces hyperlipidemia-induced inflammation and insulin resistance in skeletal muscle and adipocytes. ( Abd El-Aty, AM; Ahn, SH; Hacimuftuoglu, A; Jeong, JH; Jung, TW; Kim, HC; Park, J; Shim, JH; Shin, S; Sun, JL, 2020) |
| " Tryptophan (TRP) metabolism has attracted considerable attention due to its influence on the onset of depression via induction of inflammation." | 7.91 | Changes in tryptophan metabolism during pregnancy and postpartum periods: Potential involvement in postpartum depressive symptoms. ( Kubo, H; Morikawa, M; Mouri, A; Nabeshima, T; Nakamura, Y; Okada, T; Ozaki, N; Saito, K; Shiino, T; Teshigawara, T; Yamamoto, Y, 2019) |
| "In both cohorts, inflammation as measured by higher levels of CRP, sVCAM1 and sICAM1 was associated with kynurenine/tryptophan ratio and thus enhanced tryptophan breakdown (beta: 0." | 7.88 | Psychosocial stress and inflammation driving tryptophan breakdown in children and adolescents: A cross-sectional analysis of two cohorts. ( Carvalho, LA; Clarke, G; Díaz, LE; Gómez-Martínez, S; Marcos, A; Michels, N; Olavarria-Ramirez, L; Widhalm, K, 2018) |
| " Exercise training activates kynurenine biotransformation in skeletal muscle, which protects from neuroinflammation and leads to peripheral kynurenic acid accumulation." | 7.88 | Kynurenic Acid and Gpr35 Regulate Adipose Tissue Energy Homeostasis and Inflammation. ( Agudelo, LZ; Berggren, PO; Brodin, P; Bryzgalova, G; Cervenka, I; Correia, JC; Dadvar, S; Ferreira, DMS; Gerhart-Hines, Z; Izadi, M; Jannig, PR; Lakshmikanth, T; Martínez-Redondo, V; Midttun, Ø; Pereira, T; Pettersson-Klein, AT; Porsmyr-Palmertz, M; Ruas, JL; Sustarsic, EG; Ueland, PM, 2018) |
| "Inflammatory proteins are thought to be causally involved in the generation of aggression, possibly due to direct effects of cytokines in the central nervous system and/or by generation of inflammatory metabolites along the tryptophan-kynurenine (TRP/KYN) pathway, including KYN and its active metabolites kynurenic acid (KA), quinolinic acid (QA), and picolinic acid (PA)." | 7.83 | Tryptophan, kynurenine, and kynurenine metabolites: Relationship to lifetime aggression and inflammatory markers in human subjects. ( Brundin, L; Christensen, K; Coccaro, EF; Coussons-Read, M; Erhardt, S; Fanning, JR; Fuchs, D; Goiny, M; Lee, R, 2016) |
| "Adults with chronic kidney disease (CKD) exhibit alterations in tryptophan metabolism, mainly via the kynurenine pathway, due to higher enzymatic activity induced mainly by inflammation." | 7.83 | Tryptophan metabolism, its relation to inflammation and stress markers and association with psychological and cognitive functioning: Tasmanian Chronic Kidney Disease pilot study. ( Davies, N; Hilder, EF; Jose, MD; Karu, N; McKercher, C; Nichols, DS; Shellie, RA, 2016) |
| "Inflammation has an important physiological influence on mood and behavior." | 6.90 | Kynurenine metabolism and inflammation-induced depressed mood: A human experimental study. ( Cho, JH; Eisenberger, NI; Faull, K; Hwang, L; Irwin, MR; Kruse, JL; Olmstead, R, 2019) |
| "Kynurenic acid (KYNA) is an important bio-active product of tryptophan metabolism." | 6.82 | Kynurenic Acid Acts as a Signaling Molecule Regulating Energy Expenditure and Is Closely Associated With Metabolic Diseases. ( Liu, J; Song, Z; Zhang, XD; Zhen, D, 2022) |
| "Only in the bipolar depression group, lower KYNA was associated with worse cognitive functioning." | 5.72 | The Role of Kynurenines in Cognitive Dysfunction in Bipolar Disorder. ( Giltay, EJ; Hebbrecht, K; Morrens, M; Sabbe, B; van den Ameele, S; van Nuijs, ALN, 2022) |
| "Mastitis is one of the most serious diseases in humans and animals, especially in the modern dairy industry." | 5.62 | Kynurenic acid protects against mastitis in mice by ameliorating inflammatory responses and enhancing blood-milk barrier integrity. ( Bao, L; Chen, L; Feng, L; Fu, Y; Hu, X; Liu, Z; Wang, Y; Wu, K; Zhang, N; Zhao, C, 2021) |
| "Kynurenic acid (KYNA) is an endogenous excitatory amino acid receptor blocker, which may have an anti-inflammatory effect." | 5.42 | Kynurenic acid modulates experimentally induced inflammation in the trigeminal ganglion. ( Csáti, A; Edvinsson, L; Fülöp, F; Tajti, J; Toldi, J; Vécsei, L; Warfvinge, K, 2015) |
| "To determine whether functional vitamin B-6 insufficiency occurs in OC users and is attributable to OCs, we investigated the associations of PLP with metabolites of one-carbon metabolism, tryptophan catabolism, and inflammation in OC users, and evaluated the effects of OCs on these metabolites." | 5.20 | Metabolite profile analysis reveals association of vitamin B-6 with metabolites related to one-carbon metabolism and tryptophan catabolism but not with biomarkers of inflammation in oral contraceptive users and reveals the effects of oral contraceptives o ( Chi, YY; Coats, B; Gregory, JF; Midttun, Ø; Rios-Avila, L; Stacpoole, PW; Ueland, PM, 2015) |
| "Tryptophan catabolites (TRYCATs) are implicated in the pathophysiology of mood disorders by mediating immune-inflammation and neurodegenerative processes." | 5.12 | Tryptophan Catabolites in Bipolar Disorder: A Meta-Analysis. ( Coppens, V; De Picker, L; Giltay, EJ; Hebbrecht, K; Morrens, M; Skorobogatov, K, 2021) |
| "In schizophrenia and depression, opposite patterns of type-1 - type-2 immune response seem to be associated with differences in the activation of the enzyme indoleamine 2,3-dioxygenase (IDO) and in the tryptophan - kynurenine metabolism resulting in increased production of kynurenic acid in schizophrenia and decreased production of kynurenic acid in depression." | 4.84 | COX-2 inhibition in schizophrenia and major depression. ( Müller, N; Schwarz, MJ, 2008) |
| "Our results suggest that periodontal inflammation plays a role in local and systemic tryptophan-kynurenine metabolism." | 4.12 | Influence of periodontal inflammation on tryptophan-kynurenine metabolism: a cross-sectional study. ( Akdoğan, N; Altıngöz, SM; Balcı, N; Günhan, M; Kurgan, Ş; Önder, C; Serdar, MA, 2022) |
| "Our findings clarify that crocetin exerted antidepressant effects through its anti-inflammation, repairment of intestinal barrier, modulatory on the intestinal flora and metabolic disorders, which further regulated tryptophan metabolism and impacted mitogen-activated protein kinase (MAPK) signaling pathway to enhance neural plasticity, thereby protect neural." | 4.12 | Detection of the role of intestinal flora and tryptophan metabolism involved in antidepressant-like actions of crocetin based on a multi-omics approach. ( Chen, S; Chen, Z; Li, Q; Lin, S; Tao, Y; Tong, Y; Wang, P; Wang, T; Xu, Z, 2022) |
| "046), and neopterin was associated with the combined endpoint (recurrent ischemic stroke or death) (HR 1." | 4.02 | Neopterin and kynurenic acid as predictors of stroke recurrence and mortality: a multicentre prospective cohort study on biomarkers of inflammation measured three months after ischemic stroke. ( Alme, KN; Askim, T; Assmus, J; Knapskog, AB; Mollnes, TE; Naik, M; Næss, H; Saltvedt, I; Ueland, PM; Ulvik, A, 2021) |
| "Tryptophan catabolites ("TRYCATs") produced by the kynurenine pathway (KP) may play a role in depression pathophysiology." | 4.02 | The association between plasma tryptophan catabolites and depression: The role of symptom profiles and inflammation. ( Allers, KA; Beekman, ATF; Giltay, EJ; Keller, S; Milaneschi, Y; Niessen, HG; Penninx, BWJH; Schoevers, RA; Süssmuth, SD, 2021) |
| "While both adipose tissue accumulation and tryptophan metabolism alterations are features of human immunodeficiency virus (HIV) infection, their interplay is unclear." | 3.96 | Abdominal Adipose Tissue Is Associated With Alterations in Tryptophan-Kynurenine Metabolism and Markers of Systemic Inflammation in People With Human Immunodeficiency Virus. ( Gelpi, M; Lebech, AM; Lundgren, J; Midttun, Ø; Mocroft, A; Nielsen, SD; Trøseid, M; Ueland, PM; Ullum, H, 2020) |
| "Kynurenine pathway (KP) metabolites are believed to be a link between inflammation and depression through effects on brain glutamate receptors." | 3.96 | Associations among peripheral and central kynurenine pathway metabolites and inflammation in depression. ( Baer, W; Felger, JC; Goldsmith, DR; Haroon, E; Miller, AH; Patel, T; Welle, JR; Woolwine, BJ, 2020) |
| "Kynurenic acid (KA), an endogenous product of L-tryptophan metabolism in the kynurenine pathway, regulates adipose tissue energy homeostasis and inflammation." | 3.96 | Administration of kynurenic acid reduces hyperlipidemia-induced inflammation and insulin resistance in skeletal muscle and adipocytes. ( Abd El-Aty, AM; Ahn, SH; Hacimuftuoglu, A; Jeong, JH; Jung, TW; Kim, HC; Park, J; Shim, JH; Shin, S; Sun, JL, 2020) |
| "Kynurenic acid (KA) regulates energy homeostasis and alleviates inflammation in adipose tissue but how KA affects the atherosclerotic response in HUVECs remains unclear." | 3.91 | Kynurenic acid attenuates pro-inflammatory reactions in lipopolysaccharide-stimulated endothelial cells through the PPARδ/HO-1-dependent pathway. ( Jeong, JH; Jung, TW; Lee, T; Park, HS, 2019) |
| " These behavioral effects are associated with i/ a reversal of anxiety and reduced self-care, ii/ a decrease in parenchymal cytokine production, iii/ a modulation of the microglial reactivity and iv/ a decrease in microglial quinolinic acid production that is correlated with plasmatic peripheral production." | 3.91 | Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine. ( Abdel-Ahad, P; Blatzer, M; Callebert, J; Chrétien, F; Danckaert, A; de Maricourt, P; De Medeiros, GF; Gaillard, R; Jouvion, G; Langeron, O; Launay, JM; Maignan, A; Petit, AC; Sharshar, T; Van Steenwinckel, J; Verdonk, F; Vinckier, F, 2019) |
| " Tryptophan (TRP) metabolism has attracted considerable attention due to its influence on the onset of depression via induction of inflammation." | 3.91 | Changes in tryptophan metabolism during pregnancy and postpartum periods: Potential involvement in postpartum depressive symptoms. ( Kubo, H; Morikawa, M; Mouri, A; Nabeshima, T; Nakamura, Y; Okada, T; Ozaki, N; Saito, K; Shiino, T; Teshigawara, T; Yamamoto, Y, 2019) |
| "In both cohorts, inflammation as measured by higher levels of CRP, sVCAM1 and sICAM1 was associated with kynurenine/tryptophan ratio and thus enhanced tryptophan breakdown (beta: 0." | 3.88 | Psychosocial stress and inflammation driving tryptophan breakdown in children and adolescents: A cross-sectional analysis of two cohorts. ( Carvalho, LA; Clarke, G; Díaz, LE; Gómez-Martínez, S; Marcos, A; Michels, N; Olavarria-Ramirez, L; Widhalm, K, 2018) |
| " Exercise training activates kynurenine biotransformation in skeletal muscle, which protects from neuroinflammation and leads to peripheral kynurenic acid accumulation." | 3.88 | Kynurenic Acid and Gpr35 Regulate Adipose Tissue Energy Homeostasis and Inflammation. ( Agudelo, LZ; Berggren, PO; Brodin, P; Bryzgalova, G; Cervenka, I; Correia, JC; Dadvar, S; Ferreira, DMS; Gerhart-Hines, Z; Izadi, M; Jannig, PR; Lakshmikanth, T; Martínez-Redondo, V; Midttun, Ø; Pereira, T; Pettersson-Klein, AT; Porsmyr-Palmertz, M; Ruas, JL; Sustarsic, EG; Ueland, PM, 2018) |
| " In contrast, schizophrenia and psychosis are hypothesized to arise from increased metabolism of the NMDA receptor antagonist, kynurenic acid (KynA), leading to hypofunction of GABAergic interneurons, the disinhibition of pyramidal neurons and striatal hyperdopaminergia." | 3.85 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| "Inflammatory proteins are thought to be causally involved in the generation of aggression, possibly due to direct effects of cytokines in the central nervous system and/or by generation of inflammatory metabolites along the tryptophan-kynurenine (TRP/KYN) pathway, including KYN and its active metabolites kynurenic acid (KA), quinolinic acid (QA), and picolinic acid (PA)." | 3.83 | Tryptophan, kynurenine, and kynurenine metabolites: Relationship to lifetime aggression and inflammatory markers in human subjects. ( Brundin, L; Christensen, K; Coccaro, EF; Coussons-Read, M; Erhardt, S; Fanning, JR; Fuchs, D; Goiny, M; Lee, R, 2016) |
| "Adults with chronic kidney disease (CKD) exhibit alterations in tryptophan metabolism, mainly via the kynurenine pathway, due to higher enzymatic activity induced mainly by inflammation." | 3.83 | Tryptophan metabolism, its relation to inflammation and stress markers and association with psychological and cognitive functioning: Tasmanian Chronic Kidney Disease pilot study. ( Davies, N; Hilder, EF; Jose, MD; Karu, N; McKercher, C; Nichols, DS; Shellie, RA, 2016) |
| "Increases in plasma kynurenic acid (KYNA) concentration relate to the severity of inflammation." | 3.81 | Plasma kynurenic acid concentration in patients undergoing cardiac surgery: effect of anaesthesia. ( Dabrowski, W; Kotlinska-Hasiec, E; Nowicka-Stazka, P; Parada-Turska, J; Stazka, J; Stazka, K; Zadora, P, 2015) |
| "Circulating neopterin and kynurenine/tryptophan ratio (KTR) increase during inflammation and serve as markers of cellular immune activation, but data are sparse on other determinants of these markers and metabolites of the kynurenine pathway." | 3.79 | A community-based study on determinants of circulating markers of cellular immune activation and kynurenines: the Hordaland Health Study. ( Eussen, SJ; Midttun, Ø; Nygård, O; Tell, GS; Theofylaktopoulou, D; Ueland, PM; Ulvik, A; Vollset, SE, 2013) |
| "Sprague-Dawley rats were randomized to control, untreated colitis (ic TNBS), colitis fed with 2% PC-containing diet (3 days pre-treatment +3 days treatment after TNBS induction), colitis with kynurenic acid treatment (on day 6, n = 7) groups." | 3.78 | [Comparative study of novel therapeutic possibilities in animal experimental model of inflammatory bowel disease]. ( Boros, M; Erces, D; Ghyczy, M; Kaszaki, J; Kovács, T; Tiszlavicz, L; Tőkés, T; Varga, G; Vécsei, L, 2012) |
| "The inflammatory and motility changes in 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis were studied in anaesthetized Wistar rats following treatment with the natural NMDA-R antagonist kynurenic acid (KynA) or SZR-72, a blood-brain barrier-permeable synthetic KynA analogue." | 3.76 | N-Methyl-D-aspartate receptor antagonism decreases motility and inflammatory activation in the early phase of acute experimental colitis in the rat. ( Boros, M; Erces, D; Fazekas, B; Fülöp, F; Fülöp, M; Kaszaki, J; Kovács, T; Varga, G; Vécsei, L, 2010) |
| "Increased oxidative stress (SOX), inflammation and accelerated atherosclerosis have been reported in end-stage renal disease (ESRD), but their associations with kynurenine pathway activation remain unknown." | 3.75 | Kynurenine, quinolinic acid--the new factors linked to carotid atherosclerosis in patients with end-stage renal disease. ( Brzosko, S; Mysliwiec, M; Pawlak, D; Pawlak, K, 2009) |
| "Inflammation has an important physiological influence on mood and behavior." | 2.90 | Kynurenine metabolism and inflammation-induced depressed mood: A human experimental study. ( Cho, JH; Eisenberger, NI; Faull, K; Hwang, L; Irwin, MR; Kruse, JL; Olmstead, R, 2019) |
| "Kynurenic acid (KYNA) is an important bio-active product of tryptophan metabolism." | 2.82 | Kynurenic Acid Acts as a Signaling Molecule Regulating Energy Expenditure and Is Closely Associated With Metabolic Diseases. ( Liu, J; Song, Z; Zhang, XD; Zhen, D, 2022) |
| "Kynurenic acid (KA) is a tryptophan metabolite in the kynurenine pathway." | 1.72 | Kynurenic acid ameliorates NLRP3 inflammasome activation by blocking calcium mobilization ( Cheng, C; Cong, J; He, H; Kang, G; Li, J; Sun, T; Wang, X; Xie, Q; Xie, R; Yin, W; Zhao, X, 2022) |
| "Only in the bipolar depression group, lower KYNA was associated with worse cognitive functioning." | 1.72 | The Role of Kynurenines in Cognitive Dysfunction in Bipolar Disorder. ( Giltay, EJ; Hebbrecht, K; Morrens, M; Sabbe, B; van den Ameele, S; van Nuijs, ALN, 2022) |
| "Mastitis is one of the most serious diseases in humans and animals, especially in the modern dairy industry." | 1.62 | Kynurenic acid protects against mastitis in mice by ameliorating inflammatory responses and enhancing blood-milk barrier integrity. ( Bao, L; Chen, L; Feng, L; Fu, Y; Hu, X; Liu, Z; Wang, Y; Wu, K; Zhang, N; Zhao, C, 2021) |
| "Mastocytosis is a rare disease in which chronic symptoms, including depression, are related to mast cell accumulation and activation." | 1.43 | Mast cells' involvement in inflammation pathways linked to depression: evidence in mastocytosis. ( Alyanakian, MA; Aouba, A; Bachmeyer, C; Barète, S; Bonin, B; Chandesris, MO; Chauvet-Gelinier, JC; Côté, F; Damaj, G; Dubreuil, P; Gaillard, R; Georgin-Lavialle, S; Grandpeix-Guyodo, C; Haffen, E; Hermine, O; Launay, JM; Lortholary, O; Moura, DS; Salvador, A; Soucié, E; Teyssier, JR; Trojak, B; Vandel, P, 2016) |
| "Neurogenic inflammation has for decades been considered an important part of migraine pathophysiology." | 1.43 | KYNA analogue SZR72 modifies CFA-induced dural inflammation- regarding expression of pERK1/2 and IL-1β in the rat trigeminal ganglion. ( Edvinsson, L; Fülöp, F; Kruse, LS; Lukács, M; Tajti, J; Toldi, J; Vécsei, L; Warfvinge, K, 2016) |
| "Quinolinic acid was increased and kynurenic acid decreased over time in suicidal patients versus healthy controls." | 1.42 | A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality. ( Bay-Richter, C; Brundin, L; Erhardt, S; Guillemin, GJ; Lim, CK; Linderholm, KR; Samuelsson, M; Träskman-Bendz, L, 2015) |
| "Kynurenic acid (KYNA) is an endogenous excitatory amino acid receptor blocker, which may have an anti-inflammatory effect." | 1.42 | Kynurenic acid modulates experimentally induced inflammation in the trigeminal ganglion. ( Csáti, A; Edvinsson, L; Fülöp, F; Tajti, J; Toldi, J; Vécsei, L; Warfvinge, K, 2015) |
| "About 350 million people worldwide have type 2 diabetes (T2D)." | 1.42 | Increased Plasma Levels of Xanthurenic and Kynurenic Acids in Type 2 Diabetes. ( Oxenkrug, GF, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.72) | 18.2507 |
| 2000's | 5 (8.62) | 29.6817 |
| 2010's | 35 (60.34) | 24.3611 |
| 2020's | 17 (29.31) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Leclercq, S | 1 |
| Schwarz, M | 2 |
| Delzenne, NM | 1 |
| Stärkel, P | 1 |
| de Timary, P | 1 |
| Fang, J | 1 |
| Feng, C | 1 |
| Chen, W | 1 |
| Hou, P | 1 |
| Liu, Z | 2 |
| Zuo, M | 1 |
| Han, Y | 1 |
| Xu, C | 1 |
| Melino, G | 1 |
| Verkhratsky, A | 1 |
| Wang, Y | 2 |
| Shao, C | 1 |
| Shi, Y | 1 |
| Alme, KN | 1 |
| Ulvik, A | 2 |
| Askim, T | 1 |
| Assmus, J | 1 |
| Mollnes, TE | 1 |
| Naik, M | 1 |
| Næss, H | 1 |
| Saltvedt, I | 1 |
| Ueland, PM | 6 |
| Knapskog, AB | 1 |
| Hebbrecht, K | 2 |
| Morrens, M | 2 |
| Giltay, EJ | 3 |
| van Nuijs, ALN | 1 |
| Sabbe, B | 1 |
| van den Ameele, S | 1 |
| Zhen, D | 1 |
| Liu, J | 2 |
| Zhang, XD | 1 |
| Song, Z | 1 |
| Kurgan, Ş | 1 |
| Önder, C | 1 |
| Balcı, N | 1 |
| Akdoğan, N | 1 |
| Altıngöz, SM | 1 |
| Serdar, MA | 1 |
| Günhan, M | 1 |
| Lin, S | 1 |
| Li, Q | 1 |
| Xu, Z | 1 |
| Chen, Z | 1 |
| Tao, Y | 1 |
| Tong, Y | 1 |
| Wang, T | 1 |
| Chen, S | 1 |
| Wang, P | 1 |
| Sun, T | 1 |
| Xie, R | 1 |
| He, H | 1 |
| Xie, Q | 1 |
| Zhao, X | 1 |
| Kang, G | 1 |
| Cheng, C | 1 |
| Yin, W | 1 |
| Cong, J | 1 |
| Li, J | 1 |
| Wang, X | 2 |
| Olié, E | 1 |
| Lengvenyte, A | 1 |
| Courtet, P | 1 |
| Gelpi, M | 1 |
| Trøseid, M | 1 |
| Mocroft, A | 1 |
| Lebech, AM | 1 |
| Ullum, H | 1 |
| Midttun, Ø | 6 |
| Lundgren, J | 1 |
| Nielsen, SD | 1 |
| Haroon, E | 1 |
| Welle, JR | 1 |
| Woolwine, BJ | 1 |
| Goldsmith, DR | 1 |
| Baer, W | 1 |
| Patel, T | 1 |
| Felger, JC | 1 |
| Miller, AH | 1 |
| Jung, TW | 2 |
| Park, J | 1 |
| Sun, JL | 1 |
| Ahn, SH | 1 |
| Abd El-Aty, AM | 1 |
| Hacimuftuoglu, A | 1 |
| Kim, HC | 1 |
| Shim, JH | 1 |
| Shin, S | 1 |
| Jeong, JH | 2 |
| Baumgartner, R | 1 |
| Berg, M | 1 |
| Matic, L | 1 |
| Polyzos, KP | 1 |
| Forteza, MJ | 1 |
| Hjorth, SA | 1 |
| Schwartz, TW | 1 |
| Paulsson-Berne, G | 1 |
| Hansson, GK | 1 |
| Hedin, U | 1 |
| Ketelhuth, DFJ | 1 |
| Skorobogatov, K | 1 |
| Coppens, V | 1 |
| De Picker, L | 1 |
| Zhao, C | 1 |
| Wu, K | 1 |
| Bao, L | 1 |
| Chen, L | 2 |
| Feng, L | 1 |
| Fu, Y | 1 |
| Zhang, N | 1 |
| Hu, X | 1 |
| Milaneschi, Y | 1 |
| Allers, KA | 1 |
| Beekman, ATF | 1 |
| Keller, S | 1 |
| Schoevers, RA | 1 |
| Süssmuth, SD | 1 |
| Niessen, HG | 1 |
| Penninx, BWJH | 1 |
| Mo, Y | 1 |
| Jie, X | 1 |
| Wang, L | 1 |
| Ji, C | 1 |
| Gu, Y | 1 |
| Lu, Z | 1 |
| Liu, X | 1 |
| Garcia-Contreras, M | 1 |
| Tamayo-Garcia, A | 1 |
| Pappan, KL | 1 |
| Michelotti, GA | 1 |
| Stabler, CL | 1 |
| Ricordi, C | 1 |
| Buchwald, P | 1 |
| Wurfel, BE | 1 |
| Drevets, WC | 1 |
| Bliss, SA | 1 |
| McMillin, JR | 1 |
| Suzuki, H | 1 |
| Ford, BN | 1 |
| Morris, HM | 1 |
| Teague, TK | 1 |
| Dantzer, R | 1 |
| Savitz, JB | 1 |
| Bahrami, Z | 1 |
| Firouzi, M | 1 |
| Hashemi-Monfared, A | 1 |
| Zahednasab, H | 1 |
| Harirchian, MH | 1 |
| Agudelo, LZ | 1 |
| Ferreira, DMS | 1 |
| Cervenka, I | 1 |
| Bryzgalova, G | 1 |
| Dadvar, S | 1 |
| Jannig, PR | 1 |
| Pettersson-Klein, AT | 1 |
| Lakshmikanth, T | 1 |
| Sustarsic, EG | 1 |
| Porsmyr-Palmertz, M | 1 |
| Correia, JC | 1 |
| Izadi, M | 1 |
| Martínez-Redondo, V | 1 |
| Gerhart-Hines, Z | 1 |
| Brodin, P | 1 |
| Pereira, T | 1 |
| Berggren, PO | 1 |
| Ruas, JL | 1 |
| Michels, N | 1 |
| Clarke, G | 1 |
| Olavarria-Ramirez, L | 1 |
| Gómez-Martínez, S | 1 |
| Díaz, LE | 1 |
| Marcos, A | 1 |
| Widhalm, K | 1 |
| Carvalho, LA | 1 |
| Badawy, AA | 1 |
| Herrstedt, A | 1 |
| Bay, ML | 1 |
| Simonsen, C | 1 |
| Sundberg, A | 1 |
| Egeland, C | 1 |
| Thorsen-Streit, S | 1 |
| Djurhuus, SS | 1 |
| Magne Ueland, P | 1 |
| Pedersen, BK | 1 |
| Bo Svendsen, L | 1 |
| de Heer, P | 1 |
| Christensen, JF | 1 |
| Hojman, P | 1 |
| Teshigawara, T | 1 |
| Mouri, A | 1 |
| Kubo, H | 1 |
| Nakamura, Y | 1 |
| Shiino, T | 1 |
| Okada, T | 1 |
| Morikawa, M | 1 |
| Nabeshima, T | 1 |
| Ozaki, N | 1 |
| Yamamoto, Y | 1 |
| Saito, K | 1 |
| Verdonk, F | 1 |
| Petit, AC | 1 |
| Abdel-Ahad, P | 1 |
| Vinckier, F | 1 |
| Jouvion, G | 1 |
| de Maricourt, P | 1 |
| De Medeiros, GF | 1 |
| Danckaert, A | 1 |
| Van Steenwinckel, J | 1 |
| Blatzer, M | 1 |
| Maignan, A | 1 |
| Langeron, O | 1 |
| Sharshar, T | 1 |
| Callebert, J | 1 |
| Launay, JM | 2 |
| Chrétien, F | 1 |
| Gaillard, R | 2 |
| Lee, T | 1 |
| Park, HS | 1 |
| Kruse, JL | 1 |
| Cho, JH | 1 |
| Olmstead, R | 1 |
| Hwang, L | 1 |
| Faull, K | 1 |
| Eisenberger, NI | 1 |
| Irwin, MR | 1 |
| Theofylaktopoulou, D | 1 |
| Tell, GS | 1 |
| Vollset, SE | 1 |
| Nygård, O | 1 |
| Eussen, SJ | 1 |
| da Silva, VR | 1 |
| Rios-Avila, L | 2 |
| Lamers, Y | 1 |
| Ralat, MA | 1 |
| Quinlivan, EP | 1 |
| Garrett, TJ | 1 |
| Coats, B | 2 |
| Shankar, MN | 1 |
| Percival, SS | 1 |
| Chi, YY | 2 |
| Muller, KE | 1 |
| Stacpoole, PW | 2 |
| Gregory, JF | 2 |
| Bay-Richter, C | 1 |
| Linderholm, KR | 1 |
| Lim, CK | 1 |
| Samuelsson, M | 1 |
| Träskman-Bendz, L | 1 |
| Guillemin, GJ | 2 |
| Erhardt, S | 3 |
| Brundin, L | 2 |
| Kotlinska-Hasiec, E | 1 |
| Nowicka-Stazka, P | 2 |
| Parada-Turska, J | 2 |
| Stazka, K | 2 |
| Stazka, J | 1 |
| Zadora, P | 1 |
| Dabrowski, W | 2 |
| Oxenkrug, GF | 1 |
| Csáti, A | 1 |
| Edvinsson, L | 2 |
| Vécsei, L | 4 |
| Toldi, J | 2 |
| Fülöp, F | 3 |
| Tajti, J | 2 |
| Warfvinge, K | 2 |
| de Bie, J | 1 |
| Guest, J | 1 |
| Grant, R | 1 |
| Georgin-Lavialle, S | 1 |
| Moura, DS | 1 |
| Salvador, A | 1 |
| Chauvet-Gelinier, JC | 1 |
| Damaj, G | 1 |
| Côté, F | 1 |
| Soucié, E | 1 |
| Chandesris, MO | 1 |
| Barète, S | 1 |
| Grandpeix-Guyodo, C | 1 |
| Bachmeyer, C | 1 |
| Alyanakian, MA | 1 |
| Aouba, A | 1 |
| Lortholary, O | 1 |
| Dubreuil, P | 1 |
| Teyssier, JR | 1 |
| Trojak, B | 1 |
| Haffen, E | 1 |
| Vandel, P | 1 |
| Bonin, B | 1 |
| Hermine, O | 1 |
| Buras, A | 1 |
| Waszkiewicz, N | 1 |
| Szulc, A | 1 |
| Larsson, MK | 1 |
| Faka, A | 1 |
| Bhat, M | 1 |
| Imbeault, S | 1 |
| Goiny, M | 2 |
| Orhan, F | 1 |
| Oliveros, A | 1 |
| Ståhl, S | 1 |
| Liu, XC | 1 |
| Choi, DS | 1 |
| Sandberg, K | 1 |
| Engberg, G | 1 |
| Schwieler, L | 1 |
| Coccaro, EF | 1 |
| Lee, R | 1 |
| Fanning, JR | 1 |
| Fuchs, D | 2 |
| Christensen, K | 1 |
| Coussons-Read, M | 1 |
| Lukács, M | 1 |
| Kruse, LS | 1 |
| Karu, N | 1 |
| McKercher, C | 1 |
| Nichols, DS | 1 |
| Davies, N | 1 |
| Shellie, RA | 1 |
| Hilder, EF | 1 |
| Jose, MD | 1 |
| Birner, A | 1 |
| Platzer, M | 1 |
| Bengesser, SA | 1 |
| Dalkner, N | 1 |
| Fellendorf, FT | 1 |
| Queissner, R | 1 |
| Pilz, R | 1 |
| Rauch, P | 1 |
| Maget, A | 1 |
| Hamm, C | 1 |
| Herzog-Eberhard, S | 1 |
| Mangge, H | 1 |
| Moll, N | 1 |
| Zelzer, S | 1 |
| Schütze, G | 1 |
| Reininghaus, B | 1 |
| Kapfhammer, HP | 1 |
| Reininghaus, EZ | 1 |
| Müller, N | 3 |
| Schwarz, MJ | 3 |
| Pawlak, K | 1 |
| Brzosko, S | 1 |
| Mysliwiec, M | 1 |
| Pawlak, D | 1 |
| Schefold, JC | 1 |
| Zeden, JP | 1 |
| Fotopoulou, C | 1 |
| von Haehling, S | 1 |
| Pschowski, R | 1 |
| Hasper, D | 1 |
| Volk, HD | 1 |
| Schuett, C | 1 |
| Reinke, P | 1 |
| Varga, G | 2 |
| Erces, D | 2 |
| Fazekas, B | 1 |
| Fülöp, M | 1 |
| Kovács, T | 2 |
| Kaszaki, J | 2 |
| Boros, M | 2 |
| Cosi, C | 1 |
| Mannaioni, G | 1 |
| Cozzi, A | 1 |
| Carlà, V | 1 |
| Sili, M | 1 |
| Cavone, L | 1 |
| Maratea, D | 1 |
| Moroni, F | 1 |
| Myint, AM | 2 |
| Gong, CY | 1 |
| Li, Z | 1 |
| Wang, HM | 1 |
| Zhang, HW | 1 |
| Yang, J | 1 |
| Turski, W | 1 |
| Majdan, M | 1 |
| Tan, L | 2 |
| Yu, JT | 1 |
| Tőkés, T | 1 |
| Tiszlavicz, L | 1 |
| Ghyczy, M | 1 |
| Krause, D | 1 |
| Weidinger, E | 1 |
| Perez-De La Cruz, V | 1 |
| Santamaria, A | 1 |
| Maes, M | 1 |
| Mihaylova, I | 1 |
| Ruyter, MD | 1 |
| Kubera, M | 1 |
| Bosmans, E | 1 |
| Ren, K | 1 |
| Williams, GM | 1 |
| Hylden, JL | 1 |
| Ruda, MA | 1 |
| Dubner, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Norwegian COgnitive Impairment After STroke (NorCOAST) Study[NCT02650531] | 816 participants (Actual) | Observational | 2015-05-31 | Completed | |||
| Effects of 3-month Probiotic Mix Supplementation (L. Helveticus R-0052, B. Longum R-0175) on Gut Microbiota and Metabolome, Endocannabinoid and Immune Systems Activation, Along With Symptoms of Fatigue in Professional Dancers[NCT05567653] | 60 participants (Anticipated) | Interventional | 2022-09-21 | Recruiting | |||
| Prediction of the Therapeutic Response in Depression Based on an Early Neuro-computational Modeling Assessment of Motivation[NCT05866575] | 136 participants (Anticipated) | Interventional | 2023-06-01 | Not yet recruiting | |||
| Vitamin B6 Effects on One-Carbon Metabolism[NCT01128244] | Phase 2/Phase 3 | 13 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Vitamin B6 Dependence of One-Carbon Metabolism[NCT00877812] | 45 participants (Actual) | Interventional | 2008-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For all subjects, the concentration of plasma cystathionine in fasting blood samples taken before and after the supplementation period will provide a functional measure of vitamin B6 nutritional status. (NCT01128244)
Timeframe: Fasting blood samples will be taken at baseline and after 28 days of vitamin B6 supplementation.
| Intervention | micromol/L (Mean) | |
|---|---|---|
| Baseline prior to vitamin supplementation | After 28-days of vitamin supplementation | |
| Plasma Cystathionine Concentration | 0.14 | 0.13 |
For all subjects, the concentration of plasma pyridoxal phosphate in fasting blood samples taken before and after the supplementation period will provide a direct measure of vitamin B6 nutritional status. (NCT01128244)
Timeframe: Fasting blood samples will be taken at baseline and after 28 days of vitamin B6 supplementation.
| Intervention | nmol/L (Mean) | |
|---|---|---|
| Baseline prior to vitamin supplementation | After 28-days of vitamin supplementation | |
| Plasma Pyridoxal Phosphate Concentration | 25.8 | 143 |
Data from analysis of serine, methionine and leucine in the timed blood samples of all subjects will provide a measurement of the metabolic rate of homocysteine remethylation from serine-derived carbon before and after vitamin B6 supplementation. These flux values may be slightly higher than flux of total homocysteine remethylation in Outcome Measure 1 because of the small contribution of methionine salvage to the flux measured in Outcome Measure 2. (NCT01128244)
Timeframe: Blood samples will be taken prior to infusion and at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7.5, and 9h. Infusions will be conducted at baseline and after 28 days
| Intervention | micromol/(kg x hr) (Mean) | |
|---|---|---|
| Baseline prior to vitamin supplementation | After 28-days of vitamin supplementation | |
| Homocysteine Remethylation Flux From Serine | 6.60 | 6.92 |
For all subjects, analysis of blood samples before and after vitamin B6 supplementation will allow evaluation of discriminating biomarkers using targeted metabolite profile analysis of one-carbon metabolism and tryptophan catabolism constituents. Also, we will conduct exploratory evaluation and potential identification of new biomarkers using metabolomics analysis on subjects before and after vitamin B6 supplementation. (NCT01128244)
Timeframe: April, 2010 - June, 2014
| Intervention | microl/L (Mean) | |
|---|---|---|
| Baseline prior to vitamin supplementation | After 28-days of vitamin supplementation | |
| Secondary Analysis: Plasma 3-hydroxykynurenine Concentration | 25.9 | 27.3 |
Data from analysis of serine, methionine and leucine in the timed blood samples of all subjects will provide a measurement of the metabolic rate of total remethylation of homocysteine before and after vitamin B6 supplementation. (NCT01128244)
Timeframe: Blood samples will be taken prior to infusion and at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7.5, and 9h. Infusions will be conducted at baseline and after 28 days
| Intervention | micromol/(kg x hr) (Mean) | |
|---|---|---|
| Baseline prior to vitamin supplementation | After 28-days of vitamin supplementation | |
| Total Homocysteine Remethylation Flux | 6.07 | 5.63 |
10 reviews available for kynurenic acid and Inflammation
| Article | Year |
|---|---|
Redressing the interactions between stem cells and immune system in tissue regeneration.
Topics: Animals; Cell Adhesion Molecules; Cell Differentiation; Cell Proliferation; COVID-19; Humans; Immune | 2021 |
Kynurenic Acid Acts as a Signaling Molecule Regulating Energy Expenditure and Is Closely Associated With Metabolic Diseases.
Topics: Energy Metabolism; Female; Humans; Infant; Inflammation; Kynurenic Acid; Metabolic Diseases; Signal | 2022 |
Tryptophan Catabolites in Bipolar Disorder: A Meta-Analysis.
Topics: Bipolar Disorder; Depression; Humans; Inflammation; Kynurenic Acid; Kynurenine; Tryptophan | 2021 |
[Depression and inflammation in rheumatic diseases].
Topics: Cytokines; Depression; Humans; Hypothalamo-Hypophyseal System; Indoleamine-Pyrrole 2,3,-Dioxygenase; | 2016 |
COX-2 inhibition in schizophrenia and major depression.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Depressive Disorder, Major; Elect | 2008 |
Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects.
Topics: Animals; Anti-Inflammatory Agents; Antipsychotic Agents; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenas | 2011 |
[Kynurenic acid--a new tool in the treatment of hiperhomocysteinemia and its consequences?].
Topics: Atherosclerosis; Cardiovascular Diseases; Homocysteine; Humans; Hyperhomocysteinemia; Inflammation; | 2012 |
The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Topics: Aging; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Enzyme Inhibitors; Humans; Hunting | 2012 |
Anti-inflammatory treatment in schizophrenia.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Controlled Clinical Trials a | 2013 |
Integrative hypothesis for Huntington's disease: a brief review of experimental evidence.
Topics: Animals; Calcium; Cell Death; Disease Models, Animal; Energy Metabolism; Excitatory Amino Acids; Hum | 2007 |
3 trials available for kynurenic acid and Inflammation
45 other studies available for kynurenic acid and Inflammation
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Alterations of kynurenine pathway in alcohol use disorder and abstinence: a link with gut microbiota, peripheral inflammation and psychological symptoms.
Topics: Alcoholism; Gastrointestinal Microbiome; Humans; Inflammation; Kynurenic Acid; Kynurenine; Quinolini | 2021 |
Neopterin and kynurenic acid as predictors of stroke recurrence and mortality: a multicentre prospective cohort study on biomarkers of inflammation measured three months after ischemic stroke.
Topics: Aged; Biomarkers; Brain Ischemia; Cohort Studies; Female; Humans; Inflammation; Ischemic Stroke; Kyn | 2021 |
The Role of Kynurenines in Cognitive Dysfunction in Bipolar Disorder.
Topics: Bipolar Disorder; Cognitive Dysfunction; Humans; Inflammation; Kynurenic Acid; Kynurenine; Tryptopha | 2022 |
Influence of periodontal inflammation on tryptophan-kynurenine metabolism: a cross-sectional study.
Topics: Cross-Sectional Studies; Humans; Inflammation; Interleukin-6; Kynurenic Acid; Kynurenine; Quinolinic | 2022 |
Detection of the role of intestinal flora and tryptophan metabolism involved in antidepressant-like actions of crocetin based on a multi-omics approach.
Topics: Animals; Antidepressive Agents; Arachidonic Acid; Arginine; Cytokines; Depression; Gastrointestinal | 2022 |
Kynurenic acid ameliorates NLRP3 inflammasome activation by blocking calcium mobilization
Topics: Calcium; Carrier Proteins; Caspase 1; GTP-Binding Proteins; Humans; Inflammasomes; Inflammation; Int | 2022 |
[How can ketamine be used to manage suicidal risk?]
Topics: Anhedonia; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Hum | 2023 |
Abdominal Adipose Tissue Is Associated With Alterations in Tryptophan-Kynurenine Metabolism and Markers of Systemic Inflammation in People With Human Immunodeficiency Virus.
Topics: Abdominal Fat; Aged; Biomarkers; C-Reactive Protein; Cross-Sectional Studies; Female; HIV; HIV Infec | 2020 |
Associations among peripheral and central kynurenine pathway metabolites and inflammation in depression.
Topics: Depression; Humans; Inflammation; Kynurenic Acid; Kynurenine; Tryptophan | 2020 |
Administration of kynurenic acid reduces hyperlipidemia-induced inflammation and insulin resistance in skeletal muscle and adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Cells, Cultured; Diet, High-Fat; Hyperlipidemias; Inflammation; I | 2020 |
Evidence that a deviation in the kynurenine pathway aggravates atherosclerotic disease in humans.
Topics: Carotid Artery Diseases; Down-Regulation; Humans; Inflammation; Kynurenic Acid; Kynurenine; Macropha | 2021 |
Kynurenic acid protects against mastitis in mice by ameliorating inflammatory responses and enhancing blood-milk barrier integrity.
Topics: Animals; Anti-Inflammatory Agents; Escherichia coli; Escherichia coli Infections; Female; Heme Oxyge | 2021 |
The association between plasma tryptophan catabolites and depression: The role of symptom profiles and inflammation.
Topics: Depression; Depressive Disorder, Major; Humans; Inflammation; Kynurenic Acid; Kynurenine; Tryptophan | 2021 |
Bupi Yishen formula attenuates kidney injury in 5/6 nephrectomized rats via the tryptophan-kynurenic acid-aryl hydrocarbon receptor pathway.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Drugs, Chinese Herbal; Inflammation; Kidney; | 2021 |
Metabolomics Study of the Effects of Inflammation, Hypoxia, and High Glucose on Isolated Human Pancreatic Islets.
Topics: Biomarkers; Humans; Hyperglycemia; Hypoxia; Inflammation; Insulin; Insulin Secretion; Islets of Lang | 2017 |
Serum kynurenic acid is reduced in affective psychosis.
Topics: Adult; Affective Disorders, Psychotic; Bipolar Disorder; Corpus Striatum; Cytokines; Depression; Dep | 2017 |
The effect of minocycline on indolamine 2, 3 dioxygenase expression and the levels of kynurenic acid and quinolinic acid in LPS-activated primary rat microglia.
Topics: Animals; Brain; Cell Survival; Cells, Cultured; Indoleamine-Pyrrole 2,3,-Dioxygenase; Inflammation; | 2018 |
Kynurenic Acid and Gpr35 Regulate Adipose Tissue Energy Homeostasis and Inflammation.
Topics: Adipocytes; Adipose Tissue; Adipose Tissue, Beige; Adipose Tissue, White; Adiposity; Animals; Body W | 2018 |
Psychosocial stress and inflammation driving tryptophan breakdown in children and adolescents: A cross-sectional analysis of two cohorts.
Topics: Adolescent; C-Reactive Protein; Child; Cohort Studies; Cross-Sectional Studies; Cytokines; Depressio | 2018 |
Hypothesis kynurenic and quinolinic acids: The main players of the kynurenine pathway and opponents in inflammatory disease.
Topics: Animals; Anti-Inflammatory Agents; Humans; Immunosuppressive Agents; Inflammation; Kynurenic Acid; K | 2018 |
Changes in tryptophan metabolism during pregnancy and postpartum periods: Potential involvement in postpartum depressive symptoms.
Topics: Adult; Depression; Female; Humans; Inflammation; Kynurenic Acid; Kynurenine; Postpartum Period; Preg | 2019 |
Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine.
Topics: Animals; Antidepressive Agents; Anxiety; Anxiety Disorders; Biomarkers, Pharmacological; Depression; | 2019 |
Kynurenic acid attenuates pro-inflammatory reactions in lipopolysaccharide-stimulated endothelial cells through the PPARδ/HO-1-dependent pathway.
Topics: Apoptosis; Cell Adhesion; Cell Adhesion Molecules; Cytokines; Heme Oxygenase-1; Human Umbilical Vein | 2019 |
A community-based study on determinants of circulating markers of cellular immune activation and kynurenines: the Hordaland Health Study.
Topics: 3-Hydroxyanthranilic Acid; Aged; Aging; Biomarkers; Body Mass Index; Creatinine; Female; Humans; Inf | 2013 |
Metabolite profile analysis reveals functional effects of 28-day vitamin B-6 restriction on one-carbon metabolism and tryptophan catabolic pathways in healthy men and women.
Topics: Adult; Biomarkers; Creatine; Cystathionine; Female; Humans; Inflammation; Kynurenic Acid; Kynurenine | 2013 |
A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality.
Topics: Adult; Cytokines; Depressive Disorder; Female; Humans; Inflammation; Kynurenic Acid; Kynurenine; Mal | 2015 |
Plasma kynurenic acid concentration in patients undergoing cardiac surgery: effect of anaesthesia.
Topics: Aged; Anesthesia; Biomarkers; Cardiopulmonary Bypass; Female; Humans; Inflammation; Kynurenic Acid; | 2015 |
Increased Plasma Levels of Xanthurenic and Kynurenic Acids in Type 2 Diabetes.
Topics: 3-Hydroxyanthranilic Acid; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agen | 2015 |
Kynurenic acid modulates experimentally induced inflammation in the trigeminal ganglion.
Topics: Adjuvants, Immunologic; Animals; Biomarkers; Blotting, Western; Calcitonin Gene-Related Peptide; Dis | 2015 |
Central kynurenine pathway shift with age in women.
Topics: Adult; Aged; Aged, 80 and over; Aging; Brain; Female; Humans; Inflammation; Kynurenic Acid; Kynureni | 2016 |
Mast cells' involvement in inflammation pathways linked to depression: evidence in mastocytosis.
Topics: Depression; Depressive Disorder, Major; Female; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Inflam | 2016 |
Repeated LPS Injection Induces Distinct Changes in the Kynurenine Pathway in Mice.
Topics: Animals; Brain; Immune System; Inflammation; Kynurenic Acid; Kynurenine; Lipopolysaccharides; Male; | 2016 |
Tryptophan, kynurenine, and kynurenine metabolites: Relationship to lifetime aggression and inflammatory markers in human subjects.
Topics: Adult; Aggression; Biomarkers; C-Reactive Protein; Female; Humans; Inflammation; Interleukin-6; Kynu | 2016 |
KYNA analogue SZR72 modifies CFA-induced dural inflammation- regarding expression of pERK1/2 and IL-1β in the rat trigeminal ganglion.
Topics: Animals; Anti-Inflammatory Agents; Freund's Adjuvant; Gene Expression Regulation; Inflammation; Inte | 2016 |
Tryptophan metabolism, its relation to inflammation and stress markers and association with psychological and cognitive functioning: Tasmanian Chronic Kidney Disease pilot study.
Topics: Aged; Aged, 80 and over; Anxiety; Biomarkers; Cognition; Cross-Sectional Studies; Depression; Female | 2016 |
Increased breakdown of kynurenine towards its neurotoxic branch in bipolar disorder.
Topics: Adult; Bipolar Disorder; Brain; Case-Control Studies; Cognition; Depression; Female; Humans; Inflamm | 2017 |
Kynurenine, quinolinic acid--the new factors linked to carotid atherosclerosis in patients with end-stage renal disease.
Topics: Adult; Age Factors; Biomarkers; C-Reactive Protein; Carotid Artery Diseases; Cross-Sectional Studies | 2009 |
Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms.
Topics: 5-Hydroxytryptophan; Adult; Aged; C-Reactive Protein; Case-Control Studies; Creatinine; Female; Huma | 2009 |
N-Methyl-D-aspartate receptor antagonism decreases motility and inflammatory activation in the early phase of acute experimental colitis in the rat.
Topics: Analysis of Variance; Animals; Blood Pressure; Colitis; Colon; Disease Models, Animal; Excitatory Am | 2010 |
G-protein coupled receptor 35 (GPR35) activation and inflammatory pain: Studies on the antinociceptive effects of kynurenic acid and zaprinast.
Topics: Analgesics; Animals; Antidepressive Agents, Second-Generation; Dose-Response Relationship, Drug; Dru | 2011 |
Targeting the kynurenine pathway as a potential strategy to prevent and treat Alzheimer's disease.
Topics: Alzheimer Disease; Humans; Inflammation; Kynurenic Acid; Models, Biological; Quinolinic Acid; Recept | 2011 |
[Comparative study of novel therapeutic possibilities in animal experimental model of inflammatory bowel disease].
Topics: Administration, Oral; Animals; Biomarkers; Colitis; Disease Models, Animal; Excitatory Amino Acid An | 2012 |
The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation.
Topics: Adult; Anti-Inflammatory Agents; Cytokines; Depressive Disorder; Female; Gene Expression Regulation; | 2007 |
The intrathecal administration of excitatory amino acid receptor antagonists selectively attenuated carrageenan-induced behavioral hyperalgesia in rats.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Analgesics; Analysis of Variance; Animals; Behavior, Animal; C | 1992 |